Cargando…

Case report of a Li–Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2

BACKGROUND: Cases of multiple tumors are rarely reported in China. In our study, a 57-year-old female patient had concurrent squamous cell carcinoma, mucoepidermoid carcinoma, brain cancer, bone cancer, and thyroid cancer, which has rarely been reported to date. METHODS: To determine the relationshi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Xuehan, Li, Yongping, Cao, Hongzhi, Wang, Ting, Chen, Jianghao, Liu, Jiayun, Lin, Liya, Ye, Rui, Li, Xinyang, Liu, Shuang, Li, Weiyang, Lv, Yonggang, Zhang, Juliang, He, Chenyang, Xu, Xun, Wang, Zhen, Huang, Chen, Liu, Xiao, Wang, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265769/
https://www.ncbi.nlm.nih.gov/pubmed/27442652
http://dx.doi.org/10.1097/MD.0000000000004251
Descripción
Sumario:BACKGROUND: Cases of multiple tumors are rarely reported in China. In our study, a 57-year-old female patient had concurrent squamous cell carcinoma, mucoepidermoid carcinoma, brain cancer, bone cancer, and thyroid cancer, which has rarely been reported to date. METHODS: To determine the relationship among these multiple cancers, available DNA samples from the thyroid, lung, and skin tumors and from normal thyroid tissue were sequenced using whole exome sequencing. RESULTS: The notable discrepancies of somatic mutations among the 3 tumor tissues indicated that they arose independently, rather than metastasizing from 1 tumor. A novel deleterious germline mutation (chr22:29091846, G->A, p.H371Y) was identified in CHEK2, a Li–Fraumeni syndrome causal gene. Examining the status of this novel mutation in the patient's healthy siblings revealed its de novo origin. CONCLUSION: Our study reports the first case of Li–Fraumeni syndrome-like in Chinese patients and demonstrates the important contribution of de novo mutations in this type of rare disease.